Nikole Kimes: Preventing Allergic Disease From Birth | Stories in Life Sciences

Can the gut microbiome in the first year of life determine whether a child develops allergies, asthma, or atopic dermatitis? In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Nikole Kimes, Ph.D., Co-Founder and CEO of Siolta Therapeutics, to explore the clinical evidence behind early-life microbiome intervention and what it means for the future of allergic disease prevention.Nikole spent years studying microbial ecosystems in coral reefs before applying ecological systems thinking to the human gut. Siolta Therapeutics recently completed a Phase 2 proof-of-concept study using a defined bacterial consortia given orally in the first year of life. Results showed a 64% reduction in atopic dermatitis and a 77% reduction in food allergy, with durability past the treatment period.We cover:How the developing infant gut microbiome is linked to allergic disease riskSiolta Therapeutics' Phase 2 clinical results for atopic dermatitis and food allergy preventionHow a defined bacterial consortia is formulated from clinical data and functional optimizationWhy the first year of life is the critical immune training window for allergic diseaseThe reimbursement and funding challenges unique to prevention drug developmentHow GLP-1s and HIV PrEP demonstrate that prevention medicine can be economically viableWhat a Phase 3 pivotal study and BLA pathway looks like for a new prevention modalityNikole's advice for founders navigating a system not designed for preventionWho this is for: life sciences founders, biotech investors, clinical researchers, and healthcare professionals interested in the microbiome, early-life disease prevention, and the future of immune modulation therapies.Guest: Nikole Kimes, Ph.D.Co-Founder and CEO, Siolta Therapeuticshttps://www.sioltatherapeutics.comhttps://www.linkedin.com/in/nikole-kimes-4b357786 https://www.linkedin.com/company/siolta-therapeutics